- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 18
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 18, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 18.
Number 5: Dr Stanley Cohen, medical director of the Metroplex Clinical Research Center and clinical professor of internal medicine at the University of Texas Southwestern Medical School, says that patients should feel comfortable about using biosimilars to treat rheumatic diseases.
Number 4: A recent paper concludes that low-level anti-tumor necrosis factor anti-drug antibodies in patients with inflammatory bowel disease may be overcome by dose escalation or the addition of an immunomodulator.
Number 3: An international, multidisciplinary task force has released 8 consensus recommendations for the use of biosimilars to treat rheumatic diseases.
Number 2: On Wednesday, Pfizer filed suit against Johnson and Johnson in a Pennsylvania district court. Pfizer’s complaint alleges that the Remicade sponsor has been using anti-competitive means to block sales of its biosimilar infliximab, Inflectra.
Number 1: Dr Angus Worthing, practicing rheumatologist and vice chair of the Alliance for Transparent and Affordable Prescriptions, says that rebates for reference biologics reduce competition and lead to higher drug prices for patients.
Finally, last week, our newsletter asked for your input on the size of the cost-saving potential that biosimilar filgrastim provides to health plans. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
